What does a mitogen control value of 8.94 IU/mL indicate in a QuantiFERON‑Gold tuberculosis test?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Mitogen-NIL Value of 8.94 IU/mL: Interpretation

A mitogen-NIL value of 8.94 IU/mL indicates a robust positive mitogen response, confirming adequate immune function and validating the QuantiFERON test as interpretable. This value is well above the threshold that would raise concern for immune dysfunction or test invalidity.

Understanding the Mitogen Control

The mitogen tube serves as a positive control in QuantiFERON testing, measuring the immune system's ability to produce interferon-gamma (IFN-γ) when stimulated. The mitogen-NIL calculation subtracts background IFN-γ (from the NIL tube) from the mitogen-stimulated response.

Key Interpretation Points:

  • Your value of 8.94 IU/mL is excellent and indicates:

    • Normal T-cell function
    • Adequate immune response capability
    • Valid test results for TB antigen interpretation
    • No concern for immunosuppression affecting test performance
  • Problematic mitogen responses occur when values are low (typically <0.5 IU/mL), which can render the test indeterminate 1

Clinical Significance of Mitogen Response Levels

High Mitogen Response (Like Yours):

Your 8.94 IU/mL value is far above any concerning threshold and represents normal to robust immune function. This validates whatever TB antigen result you received (positive, negative, or borderline).

Low Mitogen Response (<0.5 IU/mL):

According to CDC guidelines, inadequate mitogen response is associated with immunosuppressive conditions and renders the test indeterminate 1. Recent research shows that even weak mitogen responses (0.5-2 IU/mL) are associated with:

  • False-negative TB results (75% in TB patients with weak mitogen vs. 20% with normal mitogen) 2
  • Ongoing infections 2
  • Increased hospital mortality 2
  • Poor prognosis in TB patients 3

Common Causes of Low Mitogen Response:

  • HIV infection with low CD4 counts 4
  • Active severe infections 2
  • Low-dose steroid therapy (even <1 mg/kg/day prednisone for <2 weeks) 5
  • Severe immunosuppression
  • Young age in children 5

What This Means for Your Test

Your mitogen response of 8.94 IU/mL confirms:

  1. The test was performed correctly
  2. Your immune system is functioning normally
  3. The TB antigen results (whether positive or negative) are reliable and interpretable
  4. No need to repeat testing due to immune concerns
  5. No concern for false-negative results due to immune dysfunction

Important Caveats

While your mitogen response is excellent, remember that:

  • The TB antigen response (not the mitogen) determines if you have latent TB infection
  • A positive TB antigen result requires evaluation for active TB disease before diagnosing latent TB 1
  • A negative TB antigen result in recent TB contacts should be repeated 8-10 weeks after exposure ends 1

Bottom line: Your mitogen-NIL of 8.94 IU/mL is reassuring and validates your QuantiFERON test results. Focus on interpreting your TB antigen response according to standard guidelines.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.